drugset / Trial / NCT00004184
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 1/2
Completed
50 enrolled
University of Alabama at Birmingham
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have stage III or stage IV melanoma at high risk for recurrence following surgery to remove the tumor.
Timeline
- Start
- 1998-08
- Primary completion
- 2001-06
- Completion
- 2001-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 4B5 | Unknown | — | Subcutaneous |
| Subject | alum adjuvant | Unknown | — | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |